PMID- 35280395
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220315
IS  - 2305-5839 (Print)
IS  - 2305-5847 (Electronic)
IS  - 2305-5839 (Linking)
VI  - 10
IP  - 4
DP  - 2022 Feb
TI  - Adverse events of different PD-1 inhibitors in lung cancer patients: a real-world 
      study.
PG  - 183
LID - 10.21037/atm-21-6899 [doi]
LID - 183
AB  - BACKGROUND: Programmed death-1 (PD-1) inhibitors have been approved and are 
      currently widely used to treat lung cancer patients. However, comparative data on 
      the adverse events (AEs) associated with different PD-1 inhibitors are very 
      limited. METHODS: Patients with histologically confirmed lung cancer who had been 
      treated with at least 1 dose of PD-1 inhibitors between January 2017 and December 
      2019 at a tertiary cancer hospital were included in the study. Data on 
      treatment-related AEs (tr-AEs) were collected from their electronic medical 
      records. RESULTS: A total of 227 lung cancer patients treated with nivolumab 
      (n=83), pembrolizumab (n=65), camrelizumab (n=27), sintilimab (n=31), and 
      toripalimab (n=21) were included. In relation to nivolumab, pembrolizumab, 
      camrelizumab, sintilimab, and toripalimab, the incidence rates of all-grade 
      tr-AEs were 37.34%, 24.62%, 62.96%, 29.03% and 9.52%, respectively (P=0.01), and 
      the incidence rates of grade 3-4 tr-AEs were 2.41%, 3.08%, 22.22%, 3.23% and 0%, 
      respectively (P=0.05). The most common all-grade tr-AEs were capillary hemangioma 
      (22.22%) and abnormal liver function (22.22%) for camrelizumab, pneumonitis for 
      nivolumab (12.05%), pembrolizumab (6.15%) and nausea/vomiting (12.9%) for 
      sintilimab, and pneumonitis (4.76%), rash/pruritus (4.76%) and shingles (4.76%) 
      for toripalimab. Sex, age, PD-1 inhibitors, histology type and PD-1 cycles were 
      significantly associated with tr-AEs. CONCLUSIONS: There were significant 
      differences in the incidence and most common tr-AEs among the different PD-1 
      inhibitors. Different monitoring priorities should be given to different PD-1 
      inhibitors during treatment cycles.
CI  - 2022 Annals of Translational Medicine. All rights reserved.
FAU - Zheng, Xiaowei
AU  - Zheng X
AD  - Department of Pharmacy, Zhejiang Provincial People's Hospital, People's Hospital 
      of Hangzhou Medical College, Hangzhou, China.
FAU - Tao, Gang
AU  - Tao G
AD  - Department of Oncology, Zhejiang Medical and Health Center Hangzhou Hospital, 
      Hangzhou, China.
FAU - Sun, Song
AU  - Sun S
AD  - Department of Radiology, Cancer Hospital of University of Chinese Academy of 
      Sciences, Institute of Cancer Research and Basic Medical Sciences of Chinese 
      Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.
FAU - Jin, Xiangni
AU  - Jin X
AD  - Department of Pharmacy, Zhejiang Provincial Hospital of Chinese Medicine, 
      Hangzhou, China.
FAU - Chen, Yanning
AU  - Chen Y
AD  - Department of Clinical Pharmacy, West China Hospital of Sichuan University, 
      Chengdu, China.
FAU - Zhang, Yiwen
AU  - Zhang Y
AD  - Department of Pharmacy, Zhejiang Provincial People's Hospital, People's Hospital 
      of Hangzhou Medical College, Hangzhou, China.
FAU - Sun, Jiao
AU  - Sun J
AD  - Department of Pharmacy, Cancer Hospital of University of Chinese Academy of 
      Sciences, Institute of Cancer Research and Basic Medical Sciences of Chinese 
      Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.
FAU - Huang, Ping
AU  - Huang P
AD  - Department of Pharmacy, Zhejiang Provincial People's Hospital, People's Hospital 
      of Hangzhou Medical College, Hangzhou, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Ann Transl Med
JT  - Annals of translational medicine
JID - 101617978
PMC - PMC8908189
OTO - NOTNLM
OT  - Programmed death-1 (PD-1)
OT  - adverse events (AEs)
OT  - lung cancer
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at 
      https://atm.amegroups.com/article/view/10.21037/atm-21-6899/coif). The authors 
      have no conflicts of interest to declare.
EDAT- 2022/03/15 06:00
MHDA- 2022/03/15 06:01
PMCR- 2022/02/01
CRDT- 2022/03/14 05:10
PHST- 2021/12/10 00:00 [received]
PHST- 2022/01/11 00:00 [accepted]
PHST- 2022/03/14 05:10 [entrez]
PHST- 2022/03/15 06:00 [pubmed]
PHST- 2022/03/15 06:01 [medline]
PHST- 2022/02/01 00:00 [pmc-release]
AID - atm-10-04-183 [pii]
AID - 10.21037/atm-21-6899 [doi]
PST - ppublish
SO  - Ann Transl Med. 2022 Feb;10(4):183. doi: 10.21037/atm-21-6899.